Cardano and Ethereum competition is still building up, with Charles Hoskinson saying that ADA will win as his legacy is dependent on it. The post ‘Cardano Will Win’: Charles Hoskinson Breaks Silence on Ethereum Rivalry appeared first on Coinspeaker.Cardano and Ethereum competition is still building up, with Charles Hoskinson saying that ADA will win as his legacy is dependent on it. The post ‘Cardano Will Win’: Charles Hoskinson Breaks Silence on Ethereum Rivalry appeared first on Coinspeaker.

‘Cardano Will Win’: Charles Hoskinson Breaks Silence on Ethereum Rivalry

The subject of Cardano ADA $0.82 24h volatility: 0.3% Market cap: $29.93 B Vol. 24h: $1.56 B and Ethereum ETH $4 395 24h volatility: 1.7% Market cap: $530.53 B Vol. 24h: $25.90 B rivalry is making rounds again, and this time around, Charles Hoskinson is putting his legacy on the line. In a recent video shared by Mintern on X, the Cardano founder stated that the Layer-1 blockchain must win against tough competitors like Ethereum.

Tough Competition Between Cardano and Ethereum

Charles Hoskinson clearly stated that his legacy depends on Cardano winning this brewing rivalry.

He claimed that he has no incentive to witness the failure of the network as his life, brand, and reputation are all tied to Cardano’s success. This is an indication that there is so much at stake for the crypto boss in the network’s triumph over its competitors.

Meanwhile, he acknowledged the challenges that Cardano had witnessed in the past. One of these is the disconnection with developers and the unavailability of practical tools like smart contracts.

However, there have been recent developments and advancements that address these challenges. This includes the Midnight and Lace Wallet, which now aligns Cardano with developers’ core needs.

Mintern left its followers and readers with the question, “Do you believe Cardano will surpass Ethereum?” While there is no exact answer to this question, it is worth noting that Cardano community members are optimistic about the possibility. Interestingly, Cardano has been outperforming Ethereum for quite a while.

In April, Coinspeaker recorded that Cardano topped Ethereum in terms of core developer activity over the past year. At the time, Cardano boasted of an impressive 21,439 GitHub commits across 550 core repositories over 12 months. This significantly placed it ahead of Ethereum, which had 20,962 commits.

Around that time, Hoskinson predicted that Ethereum would face a significant downturn by 2040. The basis for this forecast was Ethereum’s “outdated tech” and its Layer-2 fragmentation. By June, analyst Cardano Hieronymus shared some charts from CoinMarketCap on X, showing ADA outperforming Ethereum and even Solana SOL $200.2 24h volatility: 1.0% Market cap: $108.44 B Vol. 24h: $6.71 B .

Currently, ADA price is trading at $0.8352, with a 1.04% increase in the last 24 hours. Ethereum, on the other hand, is only 0.23% high within the same time frame and has seen its price go up to $4,470.76. Ethereum’s 24-hour trading is at $31.53 billion, and its market capitalization is $539.56 billion.

ETF and Treasury Reserve as a Determinant

Generally, Ethereum has seen some improvements in its ecosystem, from price to Exchange Traded Funds (ETFs).

Inflows into spot Ethereum ETFs saw a spike to a total of $1.83 billion as reported on August 28. These Ethereum funds attracted over 10x the inflows seen in their Bitcoin counterparts during the same period. Notably, the spot Bitcoin ETF saw only $171 million in inflows.

Additionally, the coin has experienced increased institutional adoption over the last few months. SharpLink and BitMine are two of the most prominent institutions in this cycle. Notably, SharpLink has as much as 800,000 ETH in its portfolio while BitMine has more than double this value.

Although Cardano is also featured in ETF applications, it has yet to garner as much traction as a treasury reserve asset.

next

The post ‘Cardano Will Win’: Charles Hoskinson Breaks Silence on Ethereum Rivalry appeared first on Coinspeaker.

Market Opportunity
Cardano Logo
Cardano Price(ADA)
$0,3909
$0,3909$0,3909
-2,25%
USD
Cardano (ADA) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Over $145M Evaporates In Brutal Long Squeeze

Over $145M Evaporates In Brutal Long Squeeze

The post Over $145M Evaporates In Brutal Long Squeeze appeared on BitcoinEthereumNews.com. Crypto Futures Liquidations: Over $145M Evaporates In Brutal Long Squeeze
Share
BitcoinEthereumNews2026/01/16 11:35
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Edges higher ahead of BoC-Fed policy outcome

Edges higher ahead of BoC-Fed policy outcome

The post Edges higher ahead of BoC-Fed policy outcome appeared on BitcoinEthereumNews.com. USD/CAD gains marginally to near 1.3760 ahead of monetary policy announcements by the Fed and the BoC. Both the Fed and the BoC are expected to lower interest rates. USD/CAD forms a Head and Shoulder chart pattern. The USD/CAD pair ticks up to near 1.3760 during the late European session on Wednesday. The Loonie pair gains marginally ahead of monetary policy outcomes by the Bank of Canada (BoC) and the Federal Reserve (Fed) during New York trading hours. Both the BoC and the Fed are expected to cut interest rates amid mounting labor market conditions in their respective economies. Inflationary pressures in the Canadian economy have cooled down, emerging as another reason behind the BoC’s dovish expectations. However, the Fed is expected to start the monetary-easing campaign despite the United States (US) inflation remaining higher. Investors will closely monitor press conferences from both Fed Chair Jerome Powell and BoC Governor Tiff Macklem to get cues about whether there will be more interest rate cuts in the remainder of the year. According to analysts from Barclays, the Fed’s latest median projections for interest rates are likely to call for three interest rate cuts by 2025. Ahead of the Fed’s monetary policy, the US Dollar Index (DXY), which tracks the Greenback’s value against six major currencies, holds onto Tuesday’s losses near 96.60. USD/CAD forms a Head and Shoulder chart pattern, which indicates a bearish reversal. The neckline of the above-mentioned chart pattern is plotted near 1.3715. The near-term trend of the pair remains bearish as it stays below the 20-day Exponential Moving Average (EMA), which trades around 1.3800. The 14-day Relative Strength Index (RSI) slides to near 40.00. A fresh bearish momentum would emerge if the RSI falls below that level. Going forward, the asset could slide towards the round level of…
Share
BitcoinEthereumNews2025/09/18 01:23